Plasma neurofilament light chain predicts Alzheimer's disease in patients with subjective cognitive decline and mild cognitive impairment: A cross‐sectional and longitudinal study
European Journal of Neurology · 2024
DOI: 10.1111/ene.16089 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Neurology, 2024. Verfasst von Salvatore Mazzeo und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction, Neurofilament Proteins. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministero della Salute, Regione Toscana.
Themen: Demenz
Abstract (Originalsprache)
Background and purpose We aimed to evaluate the accuracy of plasma neurofilament light chain (NfL) in predicting Alzheimer's disease (AD) and the progression of cognitive decline in patients with subjective cognitive decline (SCD) and mild cognitive impairment (MCI).
Methods
This longitudinal cohort study involved 140 patients (45 with SCD, 73 with MCI, and 22 with AD dementia [AD‐D]) who underwent plasma NfL and AD biomarker assessments (cerebrospinal fluid, amyloid positron emission tomography [PET], and 18 F‐fluorodeoxyglucose‐PET) at baseline. The patients were rated according to the amyloid/tau/neurodegeneration (A/T/N) system and followed up for a mean time of 2.72 ± 0.95 years to detect progression from SCD to MCI and from MCI to AD. Forty‐eight patients (19 SCD, 29 MCI) also underwent plasma NfL measurements 2 years after baseline.
Results
At baseline, plasma NfL detected patients with biomarker profiles consistent with AD (A+/T+/N+ or A+/T+/N−) with high accuracy (area under the curve [AUC] 0.82). We identified cut‐off values of 19.45 pg/mL for SCD and 20.45 pg/mL for MCI. During follow‐up, nine SCD patients progressed to MCI (progressive SCD [p‐SCD]), and 14 MCI patients developed AD dementia (progressive MCI [p‐MCI]). The previously identified cut‐off values provided good accuracy in identifying p‐SCD (80% [95% confidence interval 65.69: 94.31]). The rate of NfL change was higher in p‐MCI (3.52 ± 4.06 pg/mL) compared to non‐progressive SCD (0.81 ± 1.25 pg/mL) and non‐progressive MCI (−0.13 ± 3.24 pg/mL) patients. A rate of change lower than 1.64 pg/mL per year accurately excluded progression from MCI to AD (AUC 0.954).
Conclusion
Plasma NfL concentration and change over time may be a reliable, non‐invasive tool to detect AD and the progression of cognitive decline at the earliest stages of the disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.
- Research and Innovation Centre for Dementia-CRIDEM, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
- IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy.
- Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy.
- Regional Referral Centre for Relational Criticalities - 50139, Tuscany Region, Italy.
ORCID-Profile: Salvatore Mazzeo, Valentina Berti, Valentina Bessi
Förderung
- Ministero della Salute
- Regione Toscana
Zitieren
APA
Mazzeo, S., Ingannato, A., Giacomucci, G., Manganelli, A., Moschini, V., Balestrini, J., Cavaliere, A., Morinelli, C., Galdo, G., Emiliani, F., Piazzesi, D., Crucitti, C., Frigerio, D., Polito, C., Berti, V., Bagnoli, S., Padiglioni, S., Sorbi, S., Nacmias, B., & Bessi, V. (2024). Plasma neurofilament light chain predicts Alzheimer's disease in patients with subjective cognitive decline and mild cognitive impairment: A cross‐sectional and longitudinal study. European Journal of Neurology. https://doi.org/10.1111/ene.16089
Vancouver
Mazzeo S, Ingannato A, Giacomucci G, Manganelli A, Moschini V, Balestrini J, et al. Plasma neurofilament light chain predicts Alzheimer's disease in patients with subjective cognitive decline and mild cognitive impairment: A cross‐sectional and longitudinal study. European Journal of Neurology. 2024. doi:10.1111/ene.16089
BibTeX
@article{Mazzeo2024,
author = {Mazzeo, Salvatore and Ingannato, Assunta and Giacomucci, Giulia and Manganelli, Alberto and Moschini, Valentina and Balestrini, Juri and Cavaliere, Arianna and Morinelli, Carmen and Galdo, Giulia and Emiliani, Filippo and Piazzesi, Diletta and Crucitti, Chiara and Frigerio, Daniele and Polito, Cristina and Berti, Valentina and Bagnoli, Silvia and Padiglioni, Sonia and Sorbi, Sandro and Nacmias, Benedetta and Bessi, Valentina},
title = {Plasma neurofilament light chain predicts Alzheimer's disease in patients with subjective cognitive decline and mild cognitive impairment: A cross‐sectional and longitudinal study},
journal = {European Journal of Neurology},
year = {2024},
doi = {10.1111/ene.16089}
}
EUVIMED